What's new in Guillain-Barre syndrome in 2007-2008?(*)

Research output: Contribution to journalArticleAcademic

10 Citations (Scopus)


The years 2007 and early 2008 have been an exciting time for Guillain-Barre syndrome (GBS) research. Epidemiological studies have shown that the incidence of GBS remains stable at about 2/100,000 per year but that there have been changes in hospitalization use, likely due to the widespread availability of IVIg. Research into mechanisms has shown the importance of single amino acids in Campylobacter jejuni and the importance of ganglioside conformation. In a murine model of anti-ganglioside antibody-mediated neuropathy, Eculizumab was effective in reversing clinical disease and preventing pathology. This suggests trials of Eculizumab in GBS should be considered. Unfortunately, there are no new randomized controlled trials in GBS to report although the unmet need is great.
Original languageUndefined/Unknown
Pages (from-to)72-74
Number of pages3
JournalJournal of the Peripheral Nervous System
Issue number2
Publication statusPublished - 2009

Research programs

  • EMC MM-04-44-02

Cite this